Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-24

Clinical Trial Update: Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men. [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of RN564 in women with osteopenia and healthy men has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RN564

Snippet

Sponsor: Pfizer | Conditions: Osteopenia, Osteoporosis | Phase 1 | Status: COMPLETED | Results posted: 2024-09-24